Articles

Stockholm, Sweden—In older patients with chronic lymphocytic leukemia (CLL) and comorbidities, the use of immunotherapy with obinutuzumab (Gazyva) plus chemotherapy with chlorambucil (Leukeran) as front-line therapy was supported by the findings of the CLL11 clinical trial final analysis. Read More ›

FDA Commissioner Outlines New Plan to Increase Biosimilars by “Balancing Innovation and Competition”

By Eileen Koutnik-Fotopoulos

Healthcare Policy

TON - November 2018, Vol 11, No 5

Biosimilars are crucial for improving patient access to biologic drugs at an affordable cost. Biologics are now key in the treatment of cancer and autoimmune conditions. But cost remains an obstacle to access to drug therapy. Read More ›

Building on the Successes of Cancer Immunotherapy

By Charles Bankhead

Immunotherapy

TON - November 2018, Vol 11, No 5

Learning how to activate and harness the immune system—the body’s built-in defense against disease—has brought the field of oncology to the cusp of a cure for at least some, if not many, types of cancer, according to an international authority in immuno-oncology. Read More ›

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

By Wayne Kuznar

Immunotherapy

TON - November 2018, Vol 11, No 5

The CAR product “is essentially an autologous T-cell, which is transduced using a lentiviral encoding vector for a CAR, which is specific to human BCMA,” said Dr Raje. The co-stimulatory domain that includes 4-1BB is believed to be associated with durable CAR T-cell persistence compared with the CD28 co-stimulatory domain. Read More ›

Nivolumab plus Ipilimumab Combo Controls Brain Metastases in Patients with Melanoma

By Phoebe Starr

Melanoma

TON - November 2018, Vol 11, No 5

This clinical trial is the first study to show that this immunotherapy combination is as beneficial in controlling brain metastases as it is in treating extracranial metastases. Read More ›

TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition

By Phoebe Starr

Emerging Therapies

TON - November 2018, Vol 11, No 5

A novel approach using the investigational toll-like receptor 9 (TLR9) agonist CMP-001 in combination with pembrolizumab (Keytruda) may have the potential to reverse resistance to anti–PD-1 therapy, according to data from a preliminary phase 1b clinical trial. Read More ›

Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

There is renewed interest in MSI analysis because the MSI-H/dMMR phenotype has emerged as an actionable predictive biomarker for immune checkpoint blockade therapy in different cancer types. This review presents available evidence supporting the clinical relevance and predictive value of MSI/dMMR in cancers, including those treated with immune checkpoint inhibitors (ICIs), and outlines the diagnostic approaches developed to assess MSI/dMMR in clinical practice. Read More ›

The Importance of MSI/dMMR as Biomarkers in Oncology

By Leonard B. Saltz, MD

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

Genotyping tumors for microsatellite instability (MSI) has taken on new importance in the world of oncology. MSI screening has long been recognized as important in the care of patients with colorectal cancer (CRC) or endometrial cancer, and high-level MSI (MSI-H) is now being recognized as a potential marker for germline mutations in certain DNA mismatch-repair (MMR) genes that lead to the development of Lynch syndrome. Read More ›

Clinical Relevance and Rationale of MSI-H/dMMR as a Biomarker in Patients with Cancer

By Lauren L. Ritterhouse, MD, PhD

Faculty Perspectives: Clinical Relevance and Rationale of Using MSI-H/dMMR Biomarkers in Immunotherapy of Colorectal Cancer and Other Solid Tumors | Part 3 of a 4-Part Series

Studies examining the landscape of MSI in various cancers have shown that different tumor types tend to exhibit instability at different microsatellite loci throughout the genome, and a PCR-based test that is limited to the evaluation of only 5 loci may not adequately capture this heterogeneity. Read More ›

Expanded Access to Care for Rural Patients at Ridgecrest Regional Hospital Cancer Center

Cancer Center Profile

TON - September 2018, Vol 11, No 4

The Oncology Nurse-APN/PA spoke with Shantell Utley, OCN, MSN, BSN, RN, about how oncology teams can consult an extended network of cancer specialists by virtual tumor boards to expand access to state-of-the-art cancer care for rural patients. Read More ›

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 156 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: